The post Whale Transfers Spark $45M Sell-Side Risk as XRP Sees 31M Inflow to Binance appeared on BitcoinEthereumNews.com. Whales moved $45M in XRP to Binance, raisingThe post Whale Transfers Spark $45M Sell-Side Risk as XRP Sees 31M Inflow to Binance appeared on BitcoinEthereumNews.com. Whales moved $45M in XRP to Binance, raising

Whale Transfers Spark $45M Sell-Side Risk as XRP Sees 31M Inflow to Binance

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Whales moved $45M in XRP to Binance, raising short-term sell risk as reserves remain below 2024 highs.

Bitcoin continues to trade sideways, offering little short-term direction. Momentum remains weak as altcoins struggle to gain traction without a clear trend from BTC. In this fragile setting, large XRP transfers have raised fresh concerns about supply.

XRP Exchange Activity Spikes as Major Holders Move 31M Tokens

According to analyst Darkfost, more than 31 million XRP moved to Binance in a single day. The activity marked the week’s largest inflow spike. Binance remains a preferred venue for large holders due to its deep liquidity and tight spreads.

On-chain data shows whales drove almost all of the movement. Wallets holding over 100,000 XRP accounted for nearly the entire inflow. Smaller cohorts contributed only marginal amounts.

The breakdown by cohort shows a clear concentration among large holders. Addresses holding 100,000 to 1 million XRP transferred 14,236,825 XRP, while wallets holding 1 million or more added another 14,494,865 XRP.

In addition, mid-sized holders holding 10,000-100,000 XRP moved 2,938,809 XRP. Smaller retail wallets holding less than 10,000 XRP barely contributed.

In total, about $45 million in XRP was sent to the exchange. If those tokens are sold, they could push prices lower, especially in a market with weak liquidity. When large holders move funds to exchanges, it often suggests preparation to sell or reposition.

Market Eyes Binance XRP Balances for Signs of Broader Distribution

Current Binance reserve levels provide useful context for the recent inflow. About 2.5 billion XRP are now held on Binance. That is still far below the 2024 peak of over 3.2 billion XRP. So even though 31 million XRP moved in, overall exchange balances are not at extreme levels.

Image Source: CryptoQuant

Recent data shows reserves have stabilized, with no clear sign that large amounts of XRP are steadily moving back to exchanges. However, sustained reserve growth in coming sessions would signal deeper distribution. Persistent reserve expansion would increase supply downside risk.

Altcoins like XRP tend to be more sensitive when Bitcoin trades sideways. When BTC moves in a tight range, smaller assets can react more sharply to sudden supply changes.

At the time of writing, XRP trades near $1.395 and remains below key recovery levels. Additional selling could delay any meaningful rebound. Stable or declining exchange reserves would reduce short-term pressure.

For now, whale-driven flows on Binance remain central to XRP’s short-term outlook. Darkfost notes that concentration among large cohorts raises near-term caution. Direction will likely depend on whether those tokens enter circulation or remain parked on exchange balances.

For now, whale transfers to Binance remain the main short-term risk factor. Darkfost points out that heavy concentration among large holders calls for caution. The next price move will likely depend on whether those XRP are sold or simply held on exchange wallets.

Source: https://www.livebitcoinnews.com/whale-transfers-spark-45m-sell-side-risk-as-xrp-sees-31m-inflow-to-binance/

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.3667
$1.3667$1.3667
+0.75%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09